Pharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy
Open Access
- 27 January 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 165
Abstract
Over the past decades, remarkable progress in multimodal therapy has significantly improved survival outcomes for children with cancer. Yet, considerable variability in treatment response and toxicity persists, often driven by underlying genetic differences that affect the pharmacokinetics and pharmacodynamics of anticancer drugs. Pharmacogenomics, the study of genetic determinants of drug response, offers a powerful approach to personalize pediatric cancer therapy by optimizing efficacy while minimizing adverse effects. This review synthesizes current evidence on key pharmacogenetic variants influencing the response to major classes of antineoplastic agents used in children, including thiopurines, methotrexate, anthracyclines, alkylating agents, vinca alkaloids, and platinum compounds. Established gene–drug associations such as TPMT, NUDT15, DPYD, SLC28A3, and RARG are discussed alongside emerging biomarkers identified through genome-wide and multi-omics studies. The review also examines the major challenges that impede clinical implementation, including infrastructural limitations, cost constraints, population-specific variability, and ethical considerations. Furthermore, it highlights how integrative multi-omics, systems pharmacology, and artificial intelligence may accelerate the translation of pharmacogenomic data into clinical decision-making. The integration of pharmacogenomic testing into pediatric oncology protocols has the potential to transform cancer care by improving drug safety, enhancing treatment precision, and paving the way toward ethically grounded, personalized therapy for children.Keywords
Funding Information
- Ministry of Science and Higher Education of the Republic of Kazakhstan (BR28713341)
This publication has 60 references indexed in Scilit:
- Parental knowledge and attitudes toward genetic counseling and childhood genetic testing for congenital anomalies in QatarJournal of Genetic Counseling, 2025
- Pharmacogenomics in the UK National Health Service: Progress towards implementationBritish Journal of Clinical Pharmacology, 2025
- Recent advances in the bench-to-bedside translation of cancer nanomedicinesActa Pharmaceutica Sinica B, 2024
- Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 StudyClinical Genitourinary Cancer, 2024
- Integrating pharmacogenomic results in the electronic health record to facilitate precision medicine at a large multisite health systemJACCP: Journal of the American College of Clinical Pharmacy, 2024
- Ethical frameworks of informed consent in the age of pediatric precision medicineCambridge Prisms: Precision Medicine, 2024
- Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementationBiomedicine & Pharmacotherapy, 2023
- The role of cancer predisposition syndrome in children and adolescents with very rare tumoursEJC Paediatric Oncology, 2023
- Genetic Testing in Evaluating Risk of Anthracycline CardiomyopathyJACC: Cardiooncology, 2023
- Rapid genome sequencing for pediatricsHuman Mutation, 2022